Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition-Reference-Cited by-同舟云学术

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Published:2019-11-21 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Zhang Xuanye,Zhou Yixin,Chen Chen,Fang Wenfeng,Cai Xiuyu,Zhang Xiaoshi,Zhao Ming,Zhang Bei,Jiang Wenqi,Lin Zuan,Ma Yuxiang,Yang Yunpeng,Huang Yan,Zhao Hongyun,Xu Ruihua,Hong Shaodong^ORCID,Zhang Li

Funder

National Key R&D Program of China

National Natural Science Funds of China

Excellent Young Talents Fund Program of Higher Education Institutions of Anhui Province

Central Basic Scientific Research Fund for Colleges-Young Teacher Training Program of Sun Yat-sen University

Science and Technology Program of Guangdong Province

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0808-5.pdf

Reference27 articles.

1. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for immunotherapy of cancer. 2018;6:8.

2. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68.

3. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500.

4. Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019;5(4):497–505.

5. Loomba R, Liang TJ. Hepatitis B Reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152:1297–309.

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Photothermal therapy improves the efficacy of topical immunotherapy against melanoma;Photodiagnosis and Photodynamic Therapy;2024-10

2. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis;Liver International;2024-08-29

3. Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma;Current Oncology Reports;2024-06-05

4. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review;Cancers;2024-05-28

5. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors;Journal of Immunotherapy and Precision Oncology;2024-05-01